NAYA Bio (NAYA) Total Debt to Capital

The current NAYA Biosciences (NAYA) share price chart reflects a total debt-to-equity ratio of 3.81. The business relies on patent-protected developments in targeted tumor treatment, establishing a foundation for future market dominance. The potential for pricing power depends on the success of new immune drugs; however, the lack of profitability and early-stage testing create a critical threat of funding shortages.

NAYA Biosciences' development of innovative immunotherapeutic drugs to combat aggressive cancer correlates directly with its debt-to-equity ratio. This coefficient, defined as the ratio of total liabilities to shareholders' equity, measures the degree of financial leverage and the company's dependence on creditors, allowing investors to assess the resilience of the business model in a high-borrowing-cost environment.